Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Between 18-80 years of age at ICF signing (inclusive)
• A diagnosis of PD within 10 years from the time of ICF signing
• Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment
• All participants must understand and provide written informed consent prior to any study specific procedures
• Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments
Locations
Other Locations
Netherlands
Center for Human Drug Research
RECRUITING
Leiden
Contact Information
Primary
P.H.C. Kremer
clintrials@chdr.nl
+31 0715246400
Time Frame
Start Date: 2025-09-25
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 200
Related Therapeutic Areas
Sponsors
Leads: Vertero Therapeutics